Bausch + Lomb Inc.
http://www.bausch.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bausch + Lomb Inc.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
The Top Five Biopharma Alliances Of Q1
With the help of Biomedtracker’s Dealmaking Quarterly Statistics report, Scrip takes a look at the five biggest alliances by value in the first quarter and how they could shape the future of the companies involved, from big pharma to biotech.
Bausch Investors Initially Pessimistic Following B+L Spinout
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
Bausch Hopes B+L Spin-Out Will 'Unlock' The Value Of Eye-Care Business
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
Company Information
- Other Names / Subsidiaries
-
- Bausch & Lomb
- Bausch + Lomb Technolas
- ISTA Pharmaceuticals, Inc. (ISTA)
- Laboratorio Pförtner Cornealent SACIF, Waicon
- Technolas Perfect Vision GmbH